Oncology-focused drug development company Kazia Therapeutics (ASX:KZA) has announced the grant of patents by the respective agencies of the US and India for the manufacturing process for paxalisib.
The company said a similar patent has been accepted in Australia and is expected to proceed to grant in the third quarter of calendar year 2021.
"Further patents remain pending in the EU, China, Canada, and other strategic territories and are expected to also be approved in due course," it said.
"These newly granted manufacturing patents provide an additional layer of protection by covering the process by which paxalisib is manufactured. Any generic competitor would need to develop an alternative method of chemical synthesis, which is technically challenging and hence a costly exercise. The new patents expire in 2036," said the company.
According to CEO Dr James Garner, “As we move towards commercialisation, we have worked closely with our IP counsel to ensure we achieve the maximum possible degree and duration of protection for the intellectual property embodied in paxalisib.
"The original patents for paxalisib protect its chemical structure and have been granted in almost all relevant territories. The new suite of patents additionally covers the process by which paxalisib is manufactured and, together with the original composition of matter patents, provide exceptionally robust protection. The manufacturing patents are now granted in the US and India, and are also expected to be granted in other key territories after review by the respective patent agencies.”